| Brain atrophy in Alzheimer’s disease and aging L Pini, M Pievani, M Bocchetta, D Altomare, P Bosco, E Cavedo, ... Ageing research reviews 30, 25-48, 2016 | 729 | 2016 |
| The probabilistic model of Alzheimer disease: the amyloid hypothesis revised GB Frisoni, D Altomare, DR Thal, F Ribaldi, R van der Kant, ... Nature Reviews Neuroscience 23 (1), 53-66, 2022 | 278 | 2022 |
| Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79 (3), 228-243, 2022 | 114 | 2022 |
| European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission … F Nobili, J Arbizu, F Bouwman, A Drzezga, F Agosta, P Nestor, Z Walker, ... European Journal of Neurology 25 (10), 1201-1217, 2018 | 108 | 2018 |
| Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia Z Walker, F Gandolfo, S Orini, V Garibotto, F Agosta, J Arbizu, F Bouwman, ... European journal of nuclear medicine and molecular imaging 45, 1534-1545, 2018 | 105 | 2018 |
| Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F … M Boccardi, D Altomare, C Ferrari, C Festari, UP Guerra, B Paghera, ... JAMA neurology 73 (12), 1417-1424, 2016 | 95 | 2016 |
| Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia PJ Nestor, D Altomare, C Festari, A Drzezga, J Rivolta, Z Walker, ... European journal of nuclear medicine and molecular imaging 45, 1509-1525, 2018 | 94 | 2018 |
| Clinical utility of FDG-PET for the clinical diagnosis in MCI J Arbizu, C Festari, D Altomare, Z Walker, F Bouwman, J Rivolta, S Orini, ... European journal of nuclear medicine and molecular imaging 45, 1497-1508, 2018 | 73 | 2018 |
| Applying the ATN scheme in a memory clinic population: The ABIDE project D Altomare, A de Wilde, R Ossenkoppele, W Pelkmans, F Bouwman, ... Neurology 93 (17), e1635-e1646, 2019 | 69 | 2019 |
| Multitracer model for staging cortical amyloid deposition using PET imaging LE Collij, F Heeman, G Salvadó, S Ingala, D Altomare, A de Wilde, ... Neurology 95 (11), e1538-e1553, 2020 | 64 | 2020 |
| Diagnosis of mild cognitive impairment due to Alzheimer’s disease with transcranial magnetic stimulation A Padovani, A Benussi, V Cantoni, V Dell’Era, MS Cotelli, S Caratozzolo, ... Journal of Alzheimer's Disease 65 (1), 221-230, 2018 | 59 | 2018 |
| Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies GB Frisoni, JL Molinuevo, D Altomare, E Carrera, F Barkhof, J Berkhof, ... Alzheimer's & Dementia 16 (10), 1457-1468, 2020 | 55 | 2020 |
| Dementia prevention in memory clinics: recommendations from the European task force for brain health services GB Frisoni, D Altomare, F Ribaldi, N Villain, C Brayne, N Mukadam, ... The Lancet Regional Health–Europe 26, 2023 | 50 | 2023 |
| Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6 JM Ranson, T Rittman, S Hayat, C Brayne, F Jessen, K Blennow, ... Alzheimer's Research & Therapy 13, 1-12, 2021 | 46 | 2021 |
| AMYPAD diagnostic and patient management study: rationale and design GB Frisoni, F Barkhof, D Altomare, J Berkhof, M Boccardi, E Canzoneri, ... Alzheimer's & Dementia 15 (3), 388-399, 2019 | 40 | 2019 |
| Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 D Altomare, JL Molinuevo, C Ritchie, F Ribaldi, E Carrera, B Dubois, ... Alzheimer's research & therapy 13, 1-11, 2021 | 38 | 2021 |
| Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders F Nobili, C Festari, D Altomare, F Agosta, S Orini, K Van Laere, J Arbizu, ... European journal of nuclear medicine and molecular imaging 45, 1557-1566, 2018 | 37 | 2018 |
| Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease A Drzezga, D Altomare, C Festari, J Arbizu, S Orini, K Herholz, P Nestor, ... European journal of nuclear medicine and molecular imaging 45, 1487-1496, 2018 | 35 | 2018 |
| Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6 A Solomon, R Stephen, D Altomare, E Carrera, GB Frisoni, J Kulmala, ... Alzheimer's research & therapy 13, 1-15, 2021 | 34 | 2021 |
| Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study I Lopes Alves, LE Collij, D Altomare, GB Frisoni, L Saint‐Aubert, P Payoux, ... Alzheimer's & Dementia 16 (5), 750-758, 2020 | 34 | 2020 |
Lorenzo PiniPadova Neuroscience CenterAdresse e-mail validée de unipd.it
